COPD FOUNDATION

Thirona and COPD Foundation Launch Major AI Study to Transform COPD Treatment

13 days ago

• Thirona and the COPD Foundation have partnered to analyze over 10,000 patients in the COPDGene cohort using AI-powered quantitative CT imaging technologies to identify crucial biomarkers for COPD phenotyping. • The research will utilize Thirona's LungQ analytical capabilities, including Bronchial-Artery Analysis and Mucus Plug Quantification, to better understand COPD's heterogeneity and improve precision medicine approaches. • With COPD affecting 390 million people globally and only 15-20% of patients responding predictably to current treatments, this collaboration aims to enable more personalized therapies and enhance patient engagement through clearer disease visualization.

FDA Grants Priority Review to Dupixent for Bullous Pemphigoid Treatment

3 months ago

• The FDA has accepted Dupixent's supplemental biologics license application for priority review in treating bullous pemphigoid, with a decision expected by June 20, 2025. • Pivotal trial results showed five times more patients achieving sustained disease remission with Dupixent compared to placebo, demonstrating significant improvements in disease severity and itch reduction. • Approximately 27,000 adults in the US suffer from bullous pemphigoid uncontrolled by systemic corticosteroids, representing a significant unmet medical need in this elderly population.

Dupixent Approved by FDA as First Biologic for COPD with Eosinophilic Phenotype

8 months ago

• The FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. • Approval was based on Phase 3 trials showing significant reductions in COPD exacerbations and improvements in lung function and quality of life compared to placebo. • Dupixent targets the IL-4 and IL-13 pathways, offering a novel approach for COPD patients with type 2 inflammation and elevated blood eosinophils. • Sanofi and Regeneron's Dupixent is now the first and only approved add-on biologic medicine for inadequately controlled COPD in the US.